due dilligence is a must, but luck never hurts.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hell no, I'm still adding. lmao. ain't selling squat!
adding into short cover!!!
you'll have to google it, I got that from cnbc about a year ago.
60 mm market cap on a co. that can save millions globally...shame on mm's!
check last decembers message threads ;)
Nancy Pelowsi bought $CLNE at 3.50, I bet she's buying $CBIS
smells a fast track...
Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders;
Cannabis Science Inc., (OTC: CBIS) is pleased to announce an opportunity to directly respond to our investors regarding our corporate developments and preclinical initiatives via a 1st Q of 2013 webinar investor call. As we continue to build our team of world-renowned experts to bring CS-S/BCC-1 and CS-TATI-1 through our preclinical investigation and into subsequent human clinical studies to satisfy the FDA regulatory process for market approval both domestically and internationally.
Dr. Robert Melamede, President and CEO, states, "Over the past 3 quarters the company has successfully initiated a strong biomedical research program for the scientific investigation of our lead compound to demonstrate the anti-viral and anti-oncogenic properties based on multiple signaling pathways of cannabinoid therapeutics. In doing so we have initiated the preclinical development and initial product management of CS-TATI-1 and CS-BCC/SC-1 by appointing, Christopher Meenan MS, MBA as Executive VP of Product Research and Development, Ron Sekura PhD as Executive VP of Regulatory Affairs, Roscoe Moore DVM, MPH, PhD, Mariel Selbovitz MPH, Thomas August MD, and Dorothy Bray PhD, to the CBIS SAB team."
Cannabis Science is appointing a Chief Medical Officer and a Chief Scientific Officer to satisfy the regulatory requirements to enter into human clinical studies of CS-TATI-1 and CS-BCC/SC-1 in 2013. The Company expects to also begin initial regulatory review for consideration by federally sponsored clinical research networks in parallel to the Companies own investigations. These appointments will provide the Company with invaluable guidance as it undertakes unprecedented studies towards the commercialization of medicinal cannabinoids.
About CS-TATI-1Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About CS-S/BCC-1Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
About Cannabis Science, Inc.Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking StatementsThis Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:Cannabis Science, Inc.President and CEODr. Robert J. Melamede, 888-889-0888info@cannabisscience.com
or
VP of Investor RelationsRobert Kane, 561-234-6929rkane@cannabisscience.comwww.cannabisscience.com
SOURCE Cannabis Science, Inc.
more cheaps, kewl...
pr news wire out
can'thave these shares, adding tuesday am too. been in here too long, still have .0088 freebies.
walk up' in effect. ;)
whenever you see a short bash/dump, buy more!!!
atleast I didn't short at .o5! $CBIS weeeeeeeeeeeeeeeeeeeeeee
call them and see if they will let you do a broker assist. amtd is famous for trying to squeeze 3 bux more out of a volitile trade. gl, c4
if it holds .085, it continues run up!
3 day trendline tells all, MUCH higher!
wrong board.
much higher than .24, got the t-shirt. c4
was in cbis last dec, 20 bagged!!! confident of retest+++
retests 150dma, C4
rebought 8's, ;)
also $VRNG twits
edvacourt, 10 mins ago. updates
covered $GOOG short. :), bought calls.
mike, thanks for all your hard work. appreciated it! C4
tell em, JT!
long cbis, vrng, short goog, grpn
Carna4z
$VRNG accumulate, $CBIS 10:25 re-entry.short $GOOG,$GRPN
Nov. 9 at 8:34 AM
• Reply
• Like
• Flag
• More
and with asia 'grow out' could breach 1 bill. happy camper up here!
yup, I'm still accumulating shares here. lol AH trades proved short fear. up 10-15% eod, today ;)
1. The same judge initially accepted (see above quote) the jury’s determinations, and
2. Although the case-specific economic changes occurring from the use of two different dates would warrant a royalty rate increase, this could not account for the dramatic change contained in the Court’s ruling. In this regard, it is interesting that, although the parties agreed to an August 2006 valuation date for the hypothetical negotiation, the Court specifically relied on 2007 and 2008 information in justifying its determination of the ongoing royalty rate.
Even though the jury’s award was quadrupled, the Court concluded that the jury’s verdict should not be ignored. When explaining why the reasonable royalty rate should not be even higher, the Court wrote that plaintiff’s expert was incorrect because he failed to consider the jury’s award for past damages in his analysis.
The decision on remand has not yet been reviewed by the Federal Circuit. Regardless, since (i) the Federal Circuit determined that pre- and post-verdict royalty rates can differ, and (ii) the reasonable royalty rates can be highly case-specific and judgmental, post-verdict damages determinations will likely remain an area of significant uncertainly. Expert financial advice and testimony will be required.
http://www.hgexperts.com/article.asp?id=6354
more $GOOG rev's in works http://news.yahoo.com/google-reaches-next-billion-110251738--sector.html
sec filing stating that there has been a 'material' change in the co. ie, "award" in this case.
just stay tuned. 8-k is material, shows vrng won. hopefully very soon!
8-k out
love for cbis to give me another 20 bagger!
$VRNG in the last 30 minutes it went from a Lord Calvert night back to Crown Royal...and pepto.